Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 26;12:937934. doi: 10.3389/fonc.2022.937934

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Joseph, Cicchetti, McWilliam, Webb, Seibold, Fiorino, Cozzarini, Veldeman, Bultijnck, Fonteyne, Talbot, Symonds, Johnson, Rattay, Lambrecht, Haustermans, De Meerleer, Elliott, Sperk, Herskind, Veldwijk, Avuzzi, Giandini, Valdagni, Azria, Jacquet, Charissoux, Vega, Aguado-Barrera, Gómez-Caamaño, Franco, Garibaldi, Girelli, Iotti, Vavassori, Chang-Claude, West, Rancati and Choudhury

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Model for the worsening of at least two functional endpoints (WS2) with the inclusion of the weekly ID and stratification for the daily dose; (B) the calibration plot for the model for the worsening of at least two functional endpoints (WS2) with inclusion of the weekly ID and stratification for the daily dose evaluated on the whole REQUITE population (development population); (C) the calibration plot for the model for the worsening of at least two functional endpoints (WS2) with the inclusion of weekly ID and stratification for the daily dose evaluated on the whole DUE-01 population (independent external validation population); (D) the model for the worsening of at least three functional endpoints (WS3) with the inclusion of weekly ID and stratification for the daily dose; (E) the calibration plot for the model for the worsening of at least three functional endpoints (WS3) with the inclusion of the weekly ID and stratification for the daily dose evaluated on the whole REQUITE population (development population); (F) the calibration plot for the model for the worsening of at least three functional endpoints (WS3) with the inclusion of the weekly ID and stratification for the daily dose evaluated on the whole DUE-01 population (independent external validation population). The continuous black line represents the calibration line; its equation is given in each plot (calibration-in-the-large and calibration slope). The dotted line represents the calibration line for perfect calibration (i.e., calibration-in-the-large=0 and calibration slope=1). In (C, F), the blue line represents calibration after the exclusion of the outlier patients with predicted high risk and no worsening of functional endpoints; see the main text for details.